| Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to sever active ulcerative colitis | Life Sciences & Biotechnology, Medical Sciences | 2017 | 2020 |
| Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to severely active crohn?s disease | Life Sciences & Biotechnology, Medical Sciences | 2017 | 2021 |
| A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection | Life Sciences & Biotechnology, Medical Sciences | 2017 | 2022 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) | Life Sciences & Biotechnology, Medical Sciences | 2017 | 2022 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis | Life Sciences & Biotechnology, Medical Sciences | 2017 | 2022 |
| Association of Lipid mediators of inflammation with TB treatment outcomes | Life Sciences & Biotechnology, Medical Sciences | 2018 | 2019 |
| Cryptococcal Infections in Non HIV Infected Hosts: A Prospective International Study (MSG-11) | Life Sciences & Biotechnology, Medical Sciences | 2018 | 2020 |
| A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Ulcerative Colitis | Life Sciences & Biotechnology, Medical Sciences | 2019 | 2023 |
| A randomized, Double-blind, Placebo and Active controlled, Multicenter, Phase 3 Study to Access the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active Rheumatoid Arthritis who Are Naive to MTX Therapy | Life Sciences & Biotechnology, Medical Sciences | 2018 | 2022 |
| A randomized, double-blind, placebo and active controlled, multicenter, phase 3 study to access the efficacy and safety of Filgotinib administered for 52 weeks in combination with Methotrexate (MTX) to subjects with moderately to severely active rheumatoid arthritis, who have an inadequate response to methotrexate | Life Sciences & Biotechnology, Medical Sciences | 2018 | 2019 |